Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.       


  • Letter of Intent Due Dates: 30 days before the application due date
  • Application Due Date(s): Applications will be accepted on a rolling basis, beginning on August 26, 2019. 

PAR-19-327 Expiration Date September 2, 2022

Agency Website



Amount Description

Application budgets are limited to $5 million per year for direct costs.

The maximum period of support is 3 years

    Funding Type





    Medical - Basic Science
    Medical - Clinical Science
    Medical - Translational

    External Deadline

    September 1, 2022